Table I Spearman's Rho correlations and endpoints unique to the HNMPA-(AM)3 treatment
A Treatment started at Time 0: Early-Time Window (2–6 Days)a
HNMPA-(AM)3RapamyacinMAPK
AbbreviationPhosphoproteinAbbreviationPhosphoproteinPhosphoprotein
ACC S79Acetyl-CoA Carboxylase (Ser79)BAD S112BCL2-associated agonist of cell death (Ser112)No significant correlations
c-ABL Y245c-Abl, non-receptor tyrosine kinase (Tyr245)CRKII Y221v-crk sarcoma virus CT10 oncogene homolog (Tyr221)
CRKII Y221v-crk sarcoma virus CT10 oncogene homolog (Tyr221)IRS1 S612Insulin receptor substrate 1 (Ser612)
PTEN S380Phosphatase and tensin homolog (Ser380)p38MAPK T180/Y182p38 Mitogen Activated Protein Kinase (Thr180/Tyr182)
SRC Y527v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (Thr527)VEGFR2 Y1175Kinase insert domain receptor (a type III receptor tyrosine kinase) (Tyr1175)
STAT5 Y694Signal transducer and activator of transcription 5 (Tyr694)
B Treatment started on Day 2: Early-Time Window (2–6 Days)a
HNMPA-(AM)3MAPKRapamycin
AbbreviationPhosphoproteinAbbreviationPhosphoproteinPhosphoprotein
ACC S79Acetyl-CoA Carboxylase (Ser79)ATF2 T71Activating transcription factor 2 (Thr71)No significant correlations
AKT S473v-akt murine thymoma viral oncogene (Ser473)BAD S112BCL2-associated agonist of cell death (Ser112)
BAD S112BCL2-associated agonist of cell death (Ser112)CRKII Y221v-crk sarcoma virus CT10 oncogene homolog (Tyr221)
c-ABL Y245c-Abl, non-receptor tyrosine kinase (Tyr245)ERK 1/2 (T202/Y204)Mitogen-activated protein kinase 1/2 (T202/Y204)
CC7 D198Caspase-7, cleaved (Asp198)p38MAPK T180/Y182p38 Mitogen Activated Protein Kinase (Thr180/Tyr182)
CC9 D315Caspase-9, cleaved (Asp315)PTEN S380Phosphatase and tensin homolog (Ser380)
CRKII Y221v-crk sarcoma virus CT10 oncogene homolog (Tyr221)STAT5 Y694Signal transducer and activator of transcription 5 (Tyr694)
ERK 1/2 (T202/Y204)Mitogen-activated protein kinase 1/2 (T202/Y204)
FOX01 S256FoxO1 forkhead box O1 (Ser256)
IGF-1R (Y1131)/IR(Y1146)Insulin-like growth factor 1 receptor (Tyr1131)/Insulin Receptor (Tyr1146)
IGF-1R(Y1135/36)/IR(Y1150/51)Insulin-like growth factor 1 receptor (Try1135/36)/Insulin Receptor (Try1150/51)
IRS1 S612Insulin receptor substrate 1 (Ser612)
MST1(T183)/MST2(T180)Macrophage stimulating 1 (hepatocyte growth factor-like) (Thr183)/Mst2 (Thr180)
mTOR S2481Mechanistic target of rapamycin (Ser2481)
PDK1 S241Pyruvate dehydrogenase kinase, isozyme 1 (Ser241)
PTEN S380Phosphatase and tensin homolog (Ser380)
SRC Y527v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (Thr527)
STAT3 Y705Signal transducer and activator of transcription 3 (Y705)
STAT6 Y641Signal transducer and activator of transcription 6 (Try641)
C Early and late endpoints that are unique to the HNMPA-(AM)3 treatments
Early EndpointsLate Endpoints
AbbreviationPhosphoproteinAbbreviationPhosphoprotein
c-ABL T735bc-Abl, non-receptor tyrosine kinase (Thr735)ERK 1/2 (T202/Y204)Mitogen-activated protein kinase 1/2 (T202/Y204)
c-ABL Y245c-Abl, non-receptor tyrosine kinase (Tyr245)FADD S194Fas (TNFRSF6)-associated via death domain (Ser194)
CC7 D198Caspase-7, cleaved (Asp198)FOX01 S256FoxO1 forkhead box O1 (Ser256)
CRKII Y221bv-crk sarcoma virus CT10 oncogene homolog (Tyr221)IGF-1R(Y1131)/IR (Y1146)insulin-like growth factor 1 receptor (Tyr1131)/Insulin Receptor (Tyr1146)
FADD S194Fas (TNFRSF6)-associated via death domain (Ser194)PDK1 S241bpyruvate dehydrogenase kinase, isozyme 1 (Ser241)
IGF-1R(Y1135/36)/IR (Y1150/51)Insulin-like growth factor 1 receptor (Try1135/36)/Insulin Receptor (Try1150/51)PKA C T19b 7Protein kinase, cAMP-dependent, catalytic (Thr197)
MST1(T183)/MST2(T180)Macrophage stimulating 1 (hepatocyte growth factor-like) (Thr183)/Mst2 (Thr180)PTEN S380bPhosphatase and tensin homolog (Ser380)
mTOR S2448bMechanistic target of rapamycin (Ser2448)SMAD 1(S/S)/5(S/S)/8(S/S)bSmad family member 1 (Ser463/465)/Smad family 5 (Ser463/465)/Smad family member 8 (Ser426/428)
mTOR S2481bMechanistic target of rapamycin (Ser2481)SRC Y527bv-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (Thr527)
PDGFRb Y571platelet-derived growth factor receptor beta (Try751)STAT6 Y641Signal transducer and activator of transcription 6 (Try641)
PDK1 S241Pyruvate dehydrogenase kinase, isozyme 1 (Ser241)VEGFR2 Y1175Kinase insert domain receptor (a type III receptor tyrosine kinase) (Tyr1175)
SMAD 1(S/S)/5(S/S)/8(S/S)bSmad family member 1 (Ser463/465)/Smad family 5 (Ser463/465)/Smad family member 8 (Ser426/428)
STAT6 Y641Signal transducer and activator of transcription 6 (Try641)
  • a Spearman's Rho correlations for treatments started at time 0 and day 2 for the early time window.

  • b Endpoints in common in between Study Set #1 and HNMPA-(AM)3 treated samples.